



RECEIVED

APR 25 2003

TECH CENTER 1600/2900

LISTING OF CLAIMS

Claims 1-32 (Cancelled)

33. (Previously amended) A method of treating cancer comprising:
- (a) administration of a composition comprising *Mycobacterium phlei* (*M.phlei*)-DNA complexed on *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier; and
 - (b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.
34. (Previously added) The method of Claim 33, wherein the anti-cancer synergism is potentiation.
35. (Previously added) The method of Claim 33, wherein the composition induces cell cycle arrest in cells of the cancer, inhibits proliferation of cells of the cancer, induces apoptosis in cells of the cancer, or synchronizes cell cycles of cells of the cancer.
36. (Previously added) The method of Claim 33, wherein the cancer is leukemia, lymphoma or melanoma.
37. (Previously added) The method of Claim 33, wherein cells of the cancer display resistance against one or more chemotherapeutic agents.
38. (Previously added) The method of Claim 33, wherein the chemotherapeutic agent is administered before, after, or concurrently with the administration of the composition.

39. (Previously added) The method of Claim 33, wherein the chemotherapeutic agent is a DNA cross-linking agent, a DNA depolymerizing agent, an antimetabolic agent, an anti-tumor antibiotic agent, a topoisomerase inhibiting agent or a tubulin stabilizing agent.

40. (Previously added) The method of Claim 33, wherein the chemotherapeutic agent is mitomycin-C, 5-fluorouracil, or cisplatin.

41. (Previously amended) A method of treating cancer comprising:
(a) administration of a composition comprising *Mycobacterium phlei* (*M.phlei*)-DNA (M-DNA) and a pharmaceutically acceptable carrier; and
(b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.

42. (Previously added) The method of Claim 41, wherein the anti-cancer synergism is potentiation.

43. (Previously added) The method of Claim 41, wherein the composition induces cell cycle arrest in cells of the cancer, inhibits proliferation of cells of the cancer, induces apoptosis in cells of the cancer, or synchronizes cell cycles of cells of the cancer.

44. (Previously added) The method of Claim 41, wherein the cancer is leukemia, lymphoma or melanoma.

45. (Previously added) The method of Claim 41, wherein cells of the cancer display resistance against one or more chemotherapeutic agents.

46. (Previously added) The method of Claim 41, wherein the chemotherapeutic agent is administered before, after, or concurrently with the administration of the composition.

47. (Previously added) The method of Claim 41, wherein the chemotherapeutic agent is a DNA cross-linking agent, a DNA depolymerizing agent, an antimetabolic agent, an anti-tumor antibiotic agent, a topoisomerase inhibiting agent or a tubulin stabilizing agent.

48. (Previously added) The method of Claim 41, wherein the chemotherapeutic agent is mitomycin-C, 5-fluorouracil, or cisplatin.

49. (Previously amended) A method of treating cancer comprising:
(a) administration of a composition comprising a mycobacterial DNA complexed on mycobacterial cell wall (BCC), and a pharmaceutically acceptable carrier; and
(b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and [a] the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.

50. (Previously added) The method of Claim 49, wherein the anti-cancer synergism is potentiation.

51. (Previously added) The method of Claim 49, wherein the composition induces cell cycle arrest in cells of the cancer, inhibits proliferation of cells of the cancer, induces apoptosis in cells of the cancer, or synchronizes cell cycles of cells of the cancer.

52. (Previously added) The method of Claim 49, wherein the cancer is leukemia, lymphoma or melanoma.

53. (Previously added) The method of Claim 49, wherein cells of the cancer display resistance against one or more chemotherapeutic agents.

54. (Previously added) The method of Claim 49, wherein the chemotherapeutic agent is administered before, after, or concurrently with the administration of the composition.

55. (Previously added) The method of Claim 49, wherein the chemotherapeutic agent is a DNA cross-linking agent, a DNA depolymerizing agent, an antimetabolic agent, an anti-tumor antibiotic agent, a topoisomerase inhibiting agent or a tubulin stabilizing agent.

56. (Previously added) The method of Claim 49, wherein BCC is derived from *M. vaccae*, *M. chelonae*, *M. smegmatis*, *M. terrae*, *M. duvalii*, *M. tuberculosis*, *M. bovis BCG*, *M. avium*, *M. Szulgai*, *M. scrofulaceum*, *M. xenopi*, *M. kansaii*, *M. gastr*, *M. fortuitous*, or *M. asiaticum*.

57. (Previously amended) A method of treating cancer comprising:
(a) administration of a composition comprising a mycobacterial DNA (B-DNA), and a pharmaceutically acceptable carrier; and
(b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and [a] the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.

58. (Previously added) The method of Claim 57, wherein the anti-cancer synergism is potentiation.

59. (Previously added) The method of Claim 57, wherein the composition induces cell cycle arrest in cells of the cancer, inhibits proliferation of cells of the cancer, induces apoptosis in cells of the cancer, or synchronizes cell cycles of cells of the cancer.

60. (Previously added) The method of Claim 57, wherein the cancer is leukemia, lymphoma or melanoma.

61. (Previously added) The method of Claim 57, wherein cells of the cancer display resistance against one or more chemotherapeutic agents.

62. (Previously added) The method of Claim 57, wherein the chemotherapeutic agent is administered before, after, or concurrently with the administration of the composition.

63. (Previously added) The method of Claim 57, wherein the chemotherapeutic agent is a DNA cross-linking agent, a DNA depolymerizing agent, an antimetabolic agent, an anti-tumor antibiotic agent, a topoisomerase inhibiting agent or a tubulin stabilizing agent.

64. (Previously added) The method of Claim 57, wherein B-DNA is derived from *M. vaccae*, *M. chelonae*, *M. smegmatis*, *M. terrae*, *M. duvalii*, *M. tuberculosis*, *M. bovis BCG*, *M. avium*, *M. Szulgai*, *M. scrofulaceum*, *M. xenopi*, *M. kansaii*, *M. gastr*, *M. fortuitous*, or *M. asiaticum*.